Marinova begins expansion of fucoidan facility
The expansion is supported by the Australian government’s Modern Manufacturing Initiative, providing businesses with funding to support projects that translate high-quality research into commercial outcomes.
Photo © iStockphoto.com/pavlen
Marinova (Tasmania, Australia) started its $5 million expansion to its advanced manufacturing facility. Marinova manufactures fucoidan, a bioactive derived from brown seaweed, which has been found to support immune health, gut health, and healthy aging.
The expansion is supported by the Australian government’s Modern Manufacturing Initiative, providing businesses with funding to support projects that translate high-quality research into commercial outcomes. The project also received support through the Tasmanian government’s Building Projects Support Program and Advanced Manufacturing Accelerating Growth Program.
“This expansion will allow Marinova to triple its fucoidan production capacity,” said CEO & managing director,Paul Garrott, in a press release.“It will involve significant investment in advanced manufacturing technologies and will create highly skilled new jobs at our facility in Tasmania. This extensive capital investment will enable Marinova to readily meet the rising demand for its high purity extracts, particularly from the global medical and consumer healthcare sectors.”
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
